More than 200 land defenders died globally in 2023, Colombia deadliest
More than 200 people were murdered worldwide last year while trying to protect their lands and the environment from corporations, governments and non-state.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
More than 200 people were murdered worldwide last year while trying to protect their lands and the environment from corporations, governments and non-state.
Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.
Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments.
The European Medicines Agency is reviewing two medicines meant to treat hair loss and prostate enlargement following concerns regarding suicidal ideation and behaviours.
HQ Team October 4, 2024: Researchers at the University of Oxford have received £600,000 (€719,960) from Cancer Research UK to fund their project.
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.
The WHO has been notified of a human case of Middle East Respiratory coronavirus (MERS-CoV) in the Kingdom of Saudi Arabia.
Amplifica Holdings Group Inc.’s first-in-human trial of an injectable medicine for treating hair loss has shown a more than 15% increase in non-vellus.